Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma

Liu, D; Ma, CG; Lu, P; Gong, JF; Ye, DW; Wang, SY; Peng, PJ; Bai, YX; Song, YQ; Chen, JH; Jiang, O; Zhang, GJ; Ba, Y; Chen, L; Pan, JJ; Li, Q; Zhang, LL; Gu, SZ; Yin, XL; Cao, BW; Han, WQ; Dong, HY; Guo, JM; Zhang, HL; Su, H; Jiang, YS; Ouyang, WW; Ma, LL; Sun, Y; Zhang, F; Lv, J; Guo, YB; Xu, CY; Qi, JY; Wang, L; Wang, X; Liu, Z; Shen, L

Shen, L (corresponding author), Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Early Drug Dev Ctr,Canc Hosp & Inst, 52 Fucheng Rd, Beijing 100142, Peoples R China.

EUROPEAN JOURNAL OF CANCER, 2021; 148 (): 1

Abstract

Background: GLS-010, a novel engineered fully human immunoglobin G4 monoclonal antibody, can specially block the PD-1/PD-L1/2 axis and reactivate the ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索